Cornerstone BioPharma has a new name – – following the completion of its merger with Critical Therapeutics.

The combined company will continue to trade on the NASDAQ (Nasdaq: CRTX). Critical Therapeutics had been publicly traded. The deal enabled Cornerstone to become a public company.

Both companies had been focused on respiratory disorders.

The transaction was an all-stock swap deal. Cornerstone shareholders ended up with a 70 percent share of the combined firm.

Craig Collard, who was chief executive officer of Cornerstone BioPharma, will run the merged company. Brian Dickson, Cornerstone’s chief medical officer, will keep that title in the new firm.